August 20, 2019 / 5:20 AM / 4 months ago

BRIEF-Basilea Pharmaceutica Says H1 Net Loss Narrows To CHF 15.4 Mln

Aug 20 (Reuters) - Basilea Pharmaceutica AG:

* BASILEA REPORTS SIGNIFICANTLY INCREASED CASH-GENERATING REVENUE, FLAT OPERATING EXPENSES AND REDUCED NET LOSS FOR HALF-YEAR 2019

* TOTAL REVENUE IN FIRST HALF-YEAR 2019 INCREASED BY 5.5% TO CHF 63.2 MILLION (H1 2018: CHF 59.9 MILLION)

* H1 OPERATING LOSS AMOUNTED TO CHF 13.2 MILLION (H1 2018: CHF 20.4 MILLION)

* H1 NET LOSS WAS SIGNIFICANTLY REDUCED TO CHF 15.4 MILLION (H1 2018: CHF 22.5 MILLION)

* NET CASH USED BY OPERATING ACTIVITIES IN H2 2019 IS EXPECTED TO FURTHER DECREASE AS COMPARED TO H1 2019

* COMPANY ANTICIPATES CONTINUED STRONG REVENUE GROWTH FROM CRESEMBA AND ZEVTERA TO CHF 105-110 MILLION (+28% TO +34% Y-O-Y)

* OUTLOOK 2019: NARROWS PREVIOUS GUIDANCE ON TOTAL REVENUE TO CHF 128-133 MILLION, REFLECTING LOWER THAN PREVIOUSLY ANTICIPATED BARDA REVENUE

* OUTLOOK 2019: TOTAL COST AND OPERATING EXPENSES ARE EXPECTED TO REMAIN AT APPROXIMATELY SAME LEVEL AS 2018

* OUTLOOK 2019: ANTICIPATED OPERATING LOSS OF CHF 22-27 MILLION FOR 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below